Reviva Pharmaceuticals Stock Forecast - Naive Prediction
| RVPHWDelisted Stock | USD 0 0 25.00% |
Reviva Stock outlook is based on your current time horizon.
At this time, the value of RSI of Reviva Pharmaceuticals' share price is approaching 35 indicating that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Reviva Pharmaceuticals, making its price go up or down. Momentum 35
Sell Extended
Oversold | Overbought |
Using Reviva Pharmaceuticals hype-based prediction, you can estimate the value of Reviva Pharmaceuticals Holdings from the perspective of Reviva Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Reviva Pharmaceuticals Holdings on the next trading day is expected to be 0.01 with a mean absolute deviation of 0 and the sum of the absolute errors of 0.26. Reviva Pharmaceuticals after-hype prediction price | USD 0.002592 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Reviva |
Reviva Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Reviva price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Reviva using various technical indicators. When you analyze Reviva charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Reviva Pharmaceuticals Naive Prediction Price Forecast For the 27th of January
Given 90 days horizon, the Naive Prediction forecasted value of Reviva Pharmaceuticals Holdings on the next trading day is expected to be 0.01 with a mean absolute deviation of 0, mean absolute percentage error of 0.000034, and the sum of the absolute errors of 0.26.Please note that although there have been many attempts to predict Reviva Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Reviva Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Reviva Pharmaceuticals Stock Forecast Pattern
| Backtest Reviva Pharmaceuticals | Reviva Pharmaceuticals Price Prediction | Buy or Sell Advice |
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Reviva Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Reviva Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 107.8288 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0043 |
| MAPE | Mean absolute percentage error | 0.1744 |
| SAE | Sum of the absolute errors | 0.2599 |
Predictive Modules for Reviva Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Reviva Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Reviva Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Reviva Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Reviva Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Reviva Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Reviva Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Reviva Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Reviva Pharmaceuticals' historical news coverage. Reviva Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.00 and 13.37, respectively. We have considered Reviva Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Reviva Pharmaceuticals is out of control at this time. Analysis and calculation of next after-hype price of Reviva Pharmaceuticals is based on 3 months time horizon.
Reviva Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Reviva Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Reviva Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Reviva Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
6.36 | 13.37 | 0.38 | 0.66 | 9 Events / Month | 5 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0 | 0 | 13.59 |
|
Reviva Pharmaceuticals Hype Timeline
Reviva Pharmaceuticals is at this time traded for 0. The entity has historical hype elasticity of -0.38, and average elasticity to hype of competition of 0.66. Reviva is forecasted to decline in value after the next headline, with the price expected to drop to 0.002592. The average volatility of media hype impact on the company price is over 100%. The price reduction on the next news is expected to be -13.59%, whereas the daily expected return is at this time at -6.36%. The volatility of related hype on Reviva Pharmaceuticals is about 12980.58%, with the expected price after the next announcement by competition of 0.66. The company had not issued any dividends in recent years. Assuming the 90 days horizon the next forecasted press release will be in about 9 days. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.Reviva Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Reviva Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Reviva Pharmaceuticals' future price movements. Getting to know how Reviva Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Reviva Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MAIA | MAIA Biotechnology | (0.06) | 10 per month | 5.63 | 0.16 | 11.32 | (8.28) | 35.91 | |
| SKYE | Skye Bioscience Common | 0.01 | 18 per month | 0.00 | (0.10) | 10.19 | (7.63) | 24.11 | |
| IPSC | Century Therapeutics | (0.07) | 11 per month | 4.52 | 0.27 | 13.95 | (8.26) | 55.97 | |
| ATNM | Actinium Pharmaceuticals | 0.07 | 10 per month | 0.00 | (0.05) | 6.29 | (5.33) | 25.17 | |
| BCAB | Bioatla | 0.46 | 14 per month | 0.00 | (0.06) | 15.28 | (16.25) | 54.11 | |
| KLTO | Klotho Neurosciences | 0.04 | 16 per month | 0.00 | (0.12) | 10.34 | (8.57) | 28.13 | |
| LTRN | Lantern Pharma | 0.00 | 0 per month | 0.00 | (0.05) | 8.59 | (5.57) | 23.91 | |
| BTAI | BioXcel Therapeutics | 0.46 | 4 per month | 0.00 | (0.05) | 8.90 | (7.32) | 21.49 | |
| ATHE | Alterity Therapeutics | 0.18 | 12 per month | 0.00 | (0.09) | 5.71 | (8.48) | 17.55 | |
| CELU | Celularity | (0.06) | 20 per month | 0.00 | (0.12) | 9.01 | (8.97) | 26.97 |
Reviva Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reviva Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reviva Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reviva Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Reviva Pharmaceuticals Market Strength Events
Market strength indicators help investors to evaluate how Reviva Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Reviva Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Reviva Pharmaceuticals stock market strength indicators, traders can identify Reviva Pharmaceuticals Holdings entry and exit signals to maximize returns.
Reviva Pharmaceuticals Risk Indicators
The analysis of Reviva Pharmaceuticals' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Reviva Pharmaceuticals' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting reviva stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 10.01 | |||
| Standard Deviation | 13.37 | |||
| Variance | 178.85 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Reviva Pharmaceuticals
The number of cover stories for Reviva Pharmaceuticals depends on current market conditions and Reviva Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Reviva Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Reviva Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Reviva Pharmaceuticals Short Properties
Reviva Pharmaceuticals' future price predictability will typically decrease when Reviva Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Reviva Pharmaceuticals Holdings often depends not only on the future outlook of the potential Reviva Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Reviva Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.1 M | |
| Cash And Short Term Investments | 13.5 M | |
| Shares Float | 111.5 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Reviva Stock
If you are still planning to invest in Reviva Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reviva Pharmaceuticals' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |